- In recent times, the industrial importance of yeasts has extended beyond its traditional use in fermentation into various healthcare sectors, such as in the production of therapeutic recombinant proteins.
- The traditional baker's yeast Saccharomyces cerevisiae is one of the best-characterized eukaryotes and most widely used host systems for biopharmaceutical production since the early days of genetic engineering and recombinant protein production.
- According to this content, which of the yeasts (pichia pastoris versus saccharomyces cerevisiae) is recommended for the production of recombinant therapeutic proteins and why is better than another?
Hi there,
The main drawback of cerevisiae is that secreted proteins are most of the time hyperglycosylated and are more immunogenic when injected. For more info, see the 2 links below:
Article Pichia pastoris versus Saccharomyces cerevisiae: a case stud...
http://www.vtu-technology.com/Downloads/files/VTUTechnologyDownloads/WhataboutPichia_EBR_Samedan.pdf?m=1498459104
Dominique has given a very accurate answer to the question. However, I would not like to give blind advice on this issue as it depends upon the type of product you may be interested (it is not known from your query) and secondly what are the economics of the bioproduction of the product. This is because if the economics are good enough then it is affordable to isolate the product from the hyperglycosylated proteins of S. cerevisiae.
Pichia pastoris is preferred over Saccharomyces cerevisiae because of a few advantages with Pichia:
1. Pichia a desirable host: high biomass—cell density can be ten times greater than that of Saccharomyces cerevisiae cultures—increases production
2. Strong promoters drive high levels of expression, and
3. Efficient protein secretion signals simplify purification
However, selection of expression system is solely dependent on the aim and objectives of the research
- Badges
- Science topic
- Similar topics
- Medicine
- Disease
- Infectious Diseases